Advances in HER2 testing

Yun Chen; Liang Liu; Ronghua Ni; Weixian Zhou

doi:10.1016/bs.acc.2019.03.004

Advances in HER2 testing

Adv Clin Chem. 2019:91:123-162. doi: 10.1016/bs.acc.2019.03.004. Epub 2019 May 10.

Authors

Yun Chen¹, Liang Liu², Ronghua Ni², Weixian Zhou²

Affiliations

¹ School of Pharmacy, Nanjing Medical University, Nanjing, China. Electronic address: ychen@njmu.edu.cn.
² School of Pharmacy, Nanjing Medical University, Nanjing, China.

PMID: 31331487
DOI: 10.1016/bs.acc.2019.03.004

Abstract

HER2-positive breast cancer is a particularly aggressive type of breast cancer. Indication of HER2 positivity is essential for its treatment. In addition to a few FDA-approved methods such as immunohistochemical (IHC) detection of HER2 protein expression and in situ hybridization (ISH) assessment of HER2 gene amplification, several novel methods have been developed for HER2 testing in recent years. This chapter provides an overview of HER2 testing with emphasis on those new methods.

Keywords: Breast cancer; FISH; Gene; HER2 testing; IHC; Methods in development; Protein.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / genetics
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics*
Breast Neoplasms / pathology
Female
Genetic Predisposition to Disease*
Humans
Receptor, ErbB-2 / genetics*

Substances

Antineoplastic Agents
Biomarkers, Tumor
Receptor, ErbB-2